Leerink Swann Comments on bluebird bio, Inc.’s Q3 2017 Earnings (BLUE)
bluebird bio, Inc. (NASDAQ:BLUE) – Equities researchers at Leerink Swann decreased their Q3 2017 earnings per share (EPS) estimates for shares of bluebird bio in a report released on Wednesday. Leerink Swann analyst M. Schmidt now anticipates that the biotechnology company will post earnings per share of ($1.79) for the quarter, down from their previous estimate of ($1.67). Leerink Swann also issued estimates for bluebird bio’s Q4 2017 earnings at ($1.86) EPS, FY2017 earnings at ($7.07) EPS, FY2018 earnings at ($7.29) EPS, FY2019 earnings at ($7.46) EPS and FY2020 earnings at ($5.10) EPS.
Several other equities analysts have also recently issued reports on BLUE. Sanford C. Bernstein began coverage on bluebird bio in a research note on Thursday, July 27th. They set a “market perform” rating and a $109.00 target price on the stock. BMO Capital Markets reissued a “buy” rating and set a $108.00 target price on shares of bluebird bio in a research note on Friday. Cantor Fitzgerald set a $39.00 target price on bluebird bio and gave the company a “sell” rating in a research note on Saturday, June 24th. Cowen and Company reissued an “outperform” rating on shares of bluebird bio in a research note on Friday, June 9th. Finally, BTIG Research reissued a “buy” rating and set a $112.00 target price on shares of bluebird bio in a research note on Thursday, June 1st. Three analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. bluebird bio has an average rating of “Hold” and an average price target of $100.54.
WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was stolen and republished in violation of US and international copyright & trademark legislation. The correct version of this story can be read at https://www.americanbankingnews.com/2017/08/07/leerink-swann-comments-on-bluebird-bio-inc-s-q3-2017-earnings-blue.html.
bluebird bio (BLUE) opened at 95.05 on Monday. The company’s market capitalization is $4.33 billion. The firm’s 50 day moving average price is $102.86 and its 200-day moving average price is $88.98. bluebird bio has a 12-month low of $37.05 and a 12-month high of $123.75.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.66) by $0.07. The business had revenue of $16.70 million for the quarter, compared to the consensus estimate of $6.29 million. bluebird bio had a negative return on equity of 32.19% and a negative net margin of 1,080.59%. bluebird bio’s quarterly revenue was up 977.4% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.59) earnings per share.
In other bluebird bio news, Director Daniel Lynch sold 2,000 shares of the business’s stock in a transaction on Thursday, May 25th. The stock was sold at an average price of $80.00, for a total value of $160,000.00. Following the sale, the director now directly owns 3,400 shares of the company’s stock, valued at $272,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Jason Cole sold 17,245 shares of the business’s stock in a transaction on Wednesday, June 7th. The stock was sold at an average price of $100.22, for a total value of $1,728,293.90. Following the completion of the sale, the insider now directly owns 30,871 shares in the company, valued at $3,093,891.62. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 76,245 shares of company stock worth $7,938,108. 3.90% of the stock is owned by insiders.
A number of large investors have recently added to or reduced their stakes in BLUE. FMR LLC increased its stake in bluebird bio by 0.6% in the first quarter. FMR LLC now owns 6,126,713 shares of the biotechnology company’s stock valued at $556,918,000 after buying an additional 37,742 shares during the period. Advisors Asset Management Inc. bought a new stake in bluebird bio during the first quarter valued at approximately $858,000. Macquarie Group Ltd. bought a new stake in bluebird bio during the fourth quarter valued at approximately $703,000. Winfield Associates Inc. increased its stake in bluebird bio by 6.1% in the second quarter. Winfield Associates Inc. now owns 2,822 shares of the biotechnology company’s stock valued at $296,000 after buying an additional 162 shares during the period. Finally, Alliancebernstein L.P. increased its stake in bluebird bio by 50.1% in the first quarter. Alliancebernstein L.P. now owns 85,860 shares of the biotechnology company’s stock valued at $7,805,000 after buying an additional 28,640 shares during the period.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.